Evidence-gap map · non-drug interventions

Amyotrophic Lateral Sclerosis evidence gaps

94 registered non-drug trials, mapped by approach and outcome.

  1. Research Tracker
  2. Evidence-gap maps
  3. Amyotrophic Lateral Sclerosis

Which non-drug approaches have been tested for Amyotrophic Lateral Sclerosis, and which outcomes they were tested on. An empty cell means no matching trial was found among those searched: a possible gap, not proof that nobody has asked the question.

94registered non-drug trials
12with results posted
20recruiting as of 2026-11-16
56group × outcome cells with at least one trial
⚠️
Research information, not medical advice. These pages index what has been studied in registered trials. A trial existing, completing or posting results says nothing on its own about whether an approach works or is safe for you. Supplements and devices can interact with medicines. Discuss any change with your own clinician.

Evidence-gap matrix

Each number is the count of trials; "with results" is how many of them have posted results on ClinicalTrials.gov. A trial is counted once per group and per outcome domain it covers. The number in brackets after each group is its total trials for this condition.

none1–23–910–2930 or more
Registered non-drug trials for Amyotrophic Lateral Sclerosis by intervention group and primary outcome domain
Intervention groupFatigue and energyPost-exertional symptomsCognitionMood, anxiety and wellbeingPainSleepPhysical function and exercise capacityHeart rate, blood pressure and autonomicBreathing and lung functionQuality of lifeWeight and metabolic markersInflammation and other biomarkersSymptom severity and disease activityClinical events, survival and healthcare useFeasibility, adherence and safetyNot classified
Exercise and physical activity (15)2·1···6·41113··42 with results
Rehabilitation and therapy services (6)1···········3·21
Breathing and respiratory training (10)··11··21 with results·21···122
Mind-body and psychological approaches (7)··121·1·1211 with results·11 with results···
Diet, fasting and nutrition (8)·····1····2112321 with results
Sleep and circadian approaches (1)······1·1·······
Neuromodulation and electrical stimulation (13)····1·21 with results11··261 with results131
Oxygen, light, temperature and manual therapies (3)······21 with results····1·11·
Supplements and nutraceuticals (21)··········1483 with results341 with results5
Other devices and digital tools (1)···1············
Other behavioural, not yet classified (10)·········1·11·35

The table scrolls sideways: 16 outcome columns.

No trials found for this condition in: Cognitive training and education; Care delivery and health services.

Where the gaps are

Outcomes not found as a primary outcome in a group's trials

  • Among the 10 trials of breathing and respiratory training found, none used symptom severity and disease activity as a primary outcome (22 trials of other approaches did).
  • Among the 21 trials of supplements and nutraceuticals found, none used physical function and exercise capacity as a primary outcome (14 trials of other approaches did).
  • Among the 8 trials of diet, fasting and nutrition found, none used physical function and exercise capacity as a primary outcome (14 trials of other approaches did).
  • Among the 10 trials of breathing and respiratory training found, none used inflammation and other biomarkers as a primary outcome (10 trials of other approaches did).
  • Among the 21 trials of supplements and nutraceuticals found, none used breathing and lung function as a primary outcome (9 trials of other approaches did).
  • Among the 8 trials of diet, fasting and nutrition found, none used breathing and lung function as a primary outcome (9 trials of other approaches did).
  • Among the 15 trials of exercise and physical activity found, none used clinical events, survival and healthcare use as a primary outcome (8 trials of other approaches did).
  • Among the 21 trials of supplements and nutraceuticals found, none used quality of life as a primary outcome (5 trials of other approaches did).
  • Among the 13 trials of neuromodulation and electrical stimulation found, none used quality of life as a primary outcome (5 trials of other approaches did).
  • Among the 13 trials of neuromodulation and electrical stimulation found, none used weight and metabolic markers as a primary outcome (5 trials of other approaches did).
  • Among the 10 trials of breathing and respiratory training found, none used weight and metabolic markers as a primary outcome (5 trials of other approaches did).
  • Among the 8 trials of diet, fasting and nutrition found, none used quality of life as a primary outcome (5 trials of other approaches did).
  • Among the 21 trials of supplements and nutraceuticals found, none used mood, anxiety and wellbeing as a primary outcome (4 trials of other approaches did).
  • Among the 15 trials of exercise and physical activity found, none used mood, anxiety and wellbeing as a primary outcome (4 trials of other approaches did).

Questions studied but with no results posted

  • Exercise and physical activity × physical function and exercise capacity: 6 trials registered, none with results posted (1 still recruiting)
  • Exercise and physical activity × breathing and lung function: 4 trials registered, none with results posted (1 still recruiting)
  • Supplements and nutraceuticals × inflammation and other biomarkers: 4 trials registered, none with results posted (2 still recruiting)
  • Exercise and physical activity × symptom severity and disease activity: 3 trials registered, none with results posted
  • Rehabilitation and therapy services × symptom severity and disease activity: 3 trials registered, none with results posted (2 still recruiting)
  • Diet, fasting and nutrition × feasibility, adherence and safety: 3 trials registered, none with results posted
  • Neuromodulation and electrical stimulation × feasibility, adherence and safety: 3 trials registered, none with results posted (1 still recruiting)
  • Supplements and nutraceuticals × clinical events, survival and healthcare use: 3 trials registered, none with results posted (1 still recruiting)

Design a trial with DecenTrial (beta) Fund a component of this work

A gap here means no matching trial was found among those searched, not that an approach would work. About one trial in six has primary outcomes the rules cannot classify, so a few gaps may be measured under another name. Some gaps are gaps for good reason.

Most-studied approaches for Amyotrophic Lateral Sclerosis

Download this matrix (CSV) Non-drug evidence map Evidence brief RepurpOS condition page Condition page

How outcomes are grouped

Each trial's primary outcome measures are sorted into domains by keyword rules. 20 trials for this condition have primary outcomes the rules could not classify; they appear in the last column rather than being dropped. Checked against 90 hand-labelled outcomes; on a held-out sample of 30, the rules agreed with the hand label for 20 before adjustment, and every outcome they labelled was labelled correctly (misses were left unclassified).

Trial selection and exclusions follow the non-drug evidence map method. Source: ClinicalTrials.gov, searched 2026-11-16.